Chengda Biotech said at the 2026 semi-annual results briefing held on September 22 that the company's human diploid rabies vaccine now has large-scale production conditions, and the annual production capacity is expected to reach 10 million doses. On September 15, the first batch of the company's human diploid rabies vaccine was officially shipped and marketed from Chengda Biotech Benxi Company.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.